(Q37902946)

25 August 2017

1 reference

title

Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients (English)

1 reference

25 August 2017

1 reference

1 reference

9

Masaki Mori

1 reference

25 August 2017

10

Yuichiro Doki

1 reference

25 August 2017

4

Yukinori Kurokawa

1 reference

25 August 2017

2

Shuji Takiguchi

1 reference

25 August 2017

6

Kiyokazu Nakajima

1 reference

25 August 2017

7

Hiroshi Miyata

1 reference

25 August 2017

1

Yuichiro Hiura

1 reference

25 August 2017

3

Kazuyoshi Yamamoto

1 reference

25 August 2017

Makoto Yamasaki

5

1 reference

25 August 2017

Yoshiyuki Fujiwara

series ordinal

8

1 reference

25 August 2017

publication date

20 July 2011

1 reference

International Journal of Clinical Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

17

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

316-323

1 reference

Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Global experience with ondansetron and future potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

A role for ghrelin in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Ghrelin--a hormone with multiple functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Translational research on the clinical applications of ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Efficacy of ghrelin as a therapeutic approach for age-related physiological changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Potential of substance P antagonists as antiemetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Neuropeptide Y: A Physiological Orexigen Modulated by the Feedback Action of Ghrelin and Leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0289-0

Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer.

21 January 2018

1 reference

12 December 2020

Participation of Serotonin on Early and Delayed Emesis Induced by Initial and Subsequent Cycles of Cisplatinum‐Based Chemotherapy: Effects of Antiemetics

1 reference

12 December 2020

Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron

1 reference

12 December 2020

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Urinary serotonin metabolite excretion during cisplatin chemotherapy

1 reference

12 December 2020

Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis

1 reference

12 December 2020

1 reference

12 December 2020

The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus

1 reference

12 December 2020

Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction

1 reference

12 December 2020

10.1007/S10147-011-0289-0

Identifiers

DOI

1 reference

25 August 2017

1 reference